Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 15;127(12):2049-2061.
doi: 10.1002/cncr.33458. Epub 2021 Apr 5.

De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

Koji Sasaki  1 , Farhad Ravandi  1 , Tapan M Kadia  1 , Courtney D DiNardo  1 , Nicholas J Short  1 , Gautam Borthakur  1 , Elias Jabbour  1 , Hagop M Kantarjian  1
Affiliations

De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

Koji Sasaki et al. Cancer. .

Abstract

Background: Several important treatment and supportive care strategies have been implemented over the past 4 decades in the management of acute myeloid leukemia (AML).

Methods: The authors identified 29,107 patients who were diagnosed with de novo AML between 1980 and 2017 in the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Patients were categorized into 5 age groups (ages birth to 14, 15-39, 40-59, 60-69, and ≥70 years) and 4 calendar periods (1980-1989, 1990-1999, 2000-2009, and 2010-2017). The outcomes of patients who had AML within these categories were analyzed.

Results: The overall 5-year survival rates in patients with AML were 9%, 15%, 22%, and 28% in the decades 1980 to 1989, 1990 to 1999, 2000 to 2009, and 2010 to 2017, respectively. Among patients aged 15 to 39 years, the 5-year survival rates were 24%, 41%, 52%, and 63%, respectively; among those aged ≥70 years, the 5-year survival rates were 1%, 2%, 3%, and 5%, respectively. Four-week mortality was surprising high among adults and older patients (range, 20%-45%), even in modern times. Overall, survival continued to improve over the calendar periods and was best in the period from 2010 to 2017. Survival improvement was noticeable across all age groups except patients aged ≥70 years, in whom the estimated 5-year survival rate remained 5% even during the period from 2010 to 2017.

Conclusions: The outcomes of patients with AML showed incremental improvement over time in a population-based study of the Surveillance, Epidemiology, and End Results data. The introduction since 2017 of targeted therapies among older patients and optimizations in supportive care hopefully will continue to improve outcomes in AML, particularly among older patients.

Keywords: Epidemiology and End Results; Surveillance, Epidemiology, and End Results; acute myeloid leukemia; decades; early mortality; outcome.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no relevant conflicts of interest.

Figures

Figure 1.
Figure 1.
Survival of all types of acute myeloid leukemia by decade
Figure 1.
Figure 1.
Survival of all types of acute myeloid leukemia by decade
Figure 1.
Figure 1.
Survival of all types of acute myeloid leukemia by decade
Figure 1.
Figure 1.
Survival of all types of acute myeloid leukemia by decade
Figure 1.
Figure 1.
Survival of all types of acute myeloid leukemia by decade
Figure 1.
Figure 1.
Survival of all types of acute myeloid leukemia by decade
Figure 2.
Figure 2.
Survival of acute promyelocytic leukemia by decade
Figure 2.
Figure 2.
Survival of acute promyelocytic leukemia by decade
Figure 2.
Figure 2.
Survival of acute promyelocytic leukemia by decade
Figure 2.
Figure 2.
Survival of acute promyelocytic leukemia by decade
Figure 2.
Figure 2.
Survival of acute promyelocytic leukemia by decade
Figure 2.
Figure 2.
Survival of acute promyelocytic leukemia by decade
Figure 3.
Figure 3.
Survival of core-binding-factor acute myeloid leukemia by decade
Figure 3.
Figure 3.
Survival of core-binding-factor acute myeloid leukemia by decade
Figure 3.
Figure 3.
Survival of core-binding-factor acute myeloid leukemia by decade
Figure 3.
Figure 3.
Survival of core-binding-factor acute myeloid leukemia by decade
Figure 3.
Figure 3.
Survival of core-binding-factor acute myeloid leukemia by decade
Figure 3.
Figure 3.
Survival of core-binding-factor acute myeloid leukemia by decade
Figure 4.
Figure 4.
Survival of other types of acute myeloid leukemia by decade
Figure 4.
Figure 4.
Survival of other types of acute myeloid leukemia by decade
Figure 4.
Figure 4.
Survival of other types of acute myeloid leukemia by decade
Figure 4.
Figure 4.
Survival of other types of acute myeloid leukemia by decade
Figure 4.
Figure 4.
Survival of other types of acute myeloid leukemia by decade
Figure 4.
Figure 4.
Survival of other types of acute myeloid leukemia by decade
See this image and copyright information in PMC

References

    1. Siegel RL; Miller KD; Jemal A, Cancer statistics, 2019. CA: a cancer journal for clinicians 2019, 69 (1), 7–34. - PubMed
    1. Döhner H; Weisdorf DJ; Bloomfield CD, Acute Myeloid Leukemia. The New England journal of medicine 2015, 373 (12), 1136–52. - PubMed
    1. Kantarjian H, Acute myeloid leukemia--major progress over four decades and glimpses into the future. American journal of hematology 2016, 91 (1), 131–45. - PubMed
    1. Kadia TM; Ravandi F; Cortes J; Kantarjian H, Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. JAMA oncology 2015, 1 (6), 820–8. - PubMed
    1. Short NJ; Rytting ME; Cortes JE, Acute myeloid leukaemia. Lancet (London, England) 2018, 392 (10147), 593–606. - PMC - PubMed

LinkOut - more resources